We came across a bullish thesis on DaVita Inc. on Roche Capital’s Substack by Pedro Ortiz. In this article, we will summarize the bulls’ thesis on DVA. DaVita Inc.'s share was trading at $154.79 as of March 4th. DVA’s trailing and forward P/E were 16.01 and 11.36 respectively according to Yahoo Finance.
[caption id="attachment_567108" align="aligncenter" width="750"]DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. DVA ended 2025 as a highly profitable but...
Create a free account, or log in to read the full article
No credit card required.
We may use your email to send marketing emails about our services. Click here to read our privacy policy.